Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders.
Endocr Metab Immune Disord Drug Targets
; 9(1): 84-107, 2009 Mar.
Article
en En
| MEDLINE
| ID: mdl-19275684
ABSTRACT
The 'histone code' is a well-established hypothesis describing the idea that specific patterns of post-translational modifications to histones act like a molecular "code" recognised and used by non-histone proteins to regulate specific chromatin functions. One modification which has received significant attention is that of histone acetylation. The enzymes which regulate this modification are described as histone acetyltransferases or HATs, and histone deacetylases or HDACs [1]. Due to their conserved catalytic domain HDACs have been actively targeted as a therapeutic target. The pro-inflammatory environment is increasingly being recognised as a critical element for both degenerative diseases and cancer. The present review will discuss the current knowledge surrounding the clinical potential & current development of histone deacetylases for the treatment of diseases for which a proinflammatory environment plays important roles, and the molecular mechanisms by which such inhibitors may play important functions in modulating the proinflammatory environment.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Neoplasias de la Mama
/
Diabetes Mellitus
/
Inhibidores Enzimáticos
/
Inhibidores de Histona Desacetilasas
/
Lupus Eritematoso Sistémico
/
Esclerosis Múltiple
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Endocr Metab Immune Disord Drug Targets
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
ENDOCRINOLOGIA
/
METABOLISMO
/
TERAPIA POR MEDICAMENTOS
Año:
2009
Tipo del documento:
Article
País de afiliación:
Irlanda